Therefore, the development of a G protein-biased agonist of ADRB1 may provide a means to optimally tune ADRB1 therapeutics that will ameliorate the cognitive deficits and pathology underlying AD, as well as other neuroinflammatory diseases, without producing significant tachyphylaxis. The gene discussed is ADRB1; the disease is Alzheimer disease.